Loading…
ABVC BioPharma, Inc. is projected to rise to $1.80 by 2027, a +19% move from its current price of $1.51. ABVC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.43 | $1.51 | $1.60 | +0.01% |
| Jul 14 | $1.39 | $1.51 | $1.64 | +0.03% |
| Jul 15 | $1.37 | $1.51 | $1.67 | +0.04% |
| Jul 16 | $1.35 | $1.51 | $1.69 | +0.05% |
| Jul 17 | $1.33 | $1.51 | $1.72 | +0.07% |
| Jul 18 | $1.31 | $1.51 | $1.74 | +0.08% |
| Jul 19 | $1.30 | $1.51 | $1.76 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.30 | $1.51 | $1.76 | +0.10% |
| Week 2 | $1.22 | $1.51 | $1.87 | +0.19% |
| Week 3 | $1.17 | $1.51 | $1.97 | +0.29% |
| Week 4 | $1.12 | $1.52 | $2.05 | +0.38% |
| Week 5 | $1.08 | $1.52 | $2.13 | +0.48% |
| Week 6 | $1.05 | $1.52 | $2.20 | +0.58% |
| Week 7 | $1.02 | $1.52 | $2.27 | +0.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
ABVC BioPharma, Inc. trades at $1.45 per share and has a market capitalization of $37.7M. It holds the stock rank of 4695. The current technical backdrop combines bullish sentiment with a near-term trading range and defined support and resistance levels.
The 30-day snapshot shows a low of $0.9871 and a high of $2.13, with RSI at 50, and moving averages at SMA50 $1.31 and SMA200 $1.91, alongside support at $1.19 and resistance at $2.02.
A major floor 50.8% below — a decisive break under it would weaken the trend.
The nearest floor, 21.2% below — buyers have tended to step in here.
The nearest ceiling, 33.8% above — a clean break opens room to run.
A major ceiling 59.2% above — clearing it would confirm fresh momentum.
Key ABVC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABVC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.78 | Sell | $1.67 | Sell |
| MA 10 | $1.71 | Sell | $1.66 | Sell |
| MA 20 | $1.52 | Sell | $1.57 | Sell |
| MA 50 | $1.31 | Buy | $1.43 | Buy |
| MA 100 | $1.31 | Buy | $1.48 | Buy |
| MA 200 | $1.90 | Sell | $1.65 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.80 | Neutral |
| Stoch RSI (14) | 6.88 | Buy |
| CCI (20) | -1.94 | Neutral |
| Williams %R (14) | -71.83 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 15.27 | Buy |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 28.17 | Neutral |
| TRIX (15) | 1.31 | Buy |
| Awesome (5,34) | 0.35 | Buy |
| Ultimate (7,14,28) | 50.11 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 1.72 | Sell |
| ADX (14) | 27.76 | Sell |
| ATR (14) | 0.09 | Info |
The near-term setup indicates bullish sentiment. RSI sits at 50, and the stock trades between the 50-day and 200-day moving averages, with the SMA50 at $1.31 and SMA200 at $1.91. A clear support level is at $1.19 and a resistance barrier at $2.02, framing a 30-day price range from $0.9871 to $2.13.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.909 | $1.51 | $2.14 | 0% | Neutral | |
| $1.31 | $1.80 | $2.68 | +19% | Neutral | |
| $1.23 | $1.81 | $2.87 | +20% | Neutral | |
| $1.18 | $1.81 | $3.02 | +20% | Bullish | |
| $1.80 | $2.91 | $5.05 | +93% | Bullish | |
| $2.12 | $3.59 | $6.44 | +138% | Bullish | |
| $2.18 | $3.84 | $7.12 | +155% | Bullish | |
| $2.57 | $4.72 | $8.99 | +213% | Bullish | |
| $2.17 | $4.14 | $8.09 | +174% | Bullish | |
| $2.05 | $4.08 | $8.14 | +170% | Bullish | |
| $3.21 | $7.14 | $15.68 | +373% | Bullish | |
| $9.31 | $20.69 | $47.59 | +12.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.909 | $1.51 | $1.79 | +0.00% |
| August 2026 | $1.18 | $1.43 | $1.80 | -5.57% |
| September 2026 | $1.24 | $1.53 | $1.97 | +7.23% |
| October 2026 | $1.29 | $1.61 | $2.11 | +5.09% |
| November 2026 | $1.24 | $1.56 | $2.08 | -2.64% |
| December 2026 | $1.25 | $1.59 | $2.14 | +1.50% |
Click any year to see its month-by-month ABVC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ABVC could reach as high as $2.14, with a base case around $1.51 and support toward $0.909 — roughly 0% from $1.51. A consolidation phase looks the most probable path here.
Expect ABVC to range from $1.31 to $2.68 through 2027. The $1.80 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. Price action looks broadly range-bound.
The ABVC price prediction for 2028 points to an average of $1.81 (low $1.23, high $2.87) — a potential gain of +20% on today's $1.51. A consolidation phase looks the most probable path here.
In 2029, ABVC is projected to trade between $1.18 and $3.02, averaging $1.81 — a potential gain of +20% from today's $1.51. That is up 0% on the projected 2028 average. Momentum favours further upside here.
ABVC BioPharma, Inc.'s 2030 outlook centres on $2.91, within a $1.80 to $5.05 range. That is up +60% on the projected 2029 average. That marks a +93% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, ABVC could reach as high as $6.44, with a base case around $3.59 and support toward $2.12 — roughly +138% from $1.51. Momentum favours further upside here.
Expect ABVC to range from $2.18 to $7.12 through 2032. The $3.84 average target implies a +155% move from current prices. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The ABVC price prediction for 2033 points to an average of $4.72 (low $2.57, high $8.99) — a potential gain of +213% on today's $1.51. Momentum favours further upside here.
In 2034, ABVC is projected to trade between $2.17 and $8.09, averaging $4.14 — a potential gain of +174% from today's $1.51. That is -12% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
ABVC BioPharma, Inc.'s 2035 outlook centres on $4.08, within a $2.05 to $8.14 range. That is -2% versus the projected 2034 average. That marks a +170% change versus current levels. Momentum favours further upside here.
By 2040, ABVC could reach as high as $15.68, with a base case around $7.14 and support toward $3.21 — roughly +373% from $1.51. Buyers look set to stay in control over this stretch.
Expect ABVC to range from $9.31 to $47.59 through 2050. The $20.69 average target implies a +12.7x move from current prices. That is up +190% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ABVC today (≈ 662.251656 ABVC) could be worth
$13,704.12
+$12,704.12 (+1270%) by 2050 · US Dollar
Based on the average projected ABVC price of $20.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABVCwould be worth at today's price.
$1,000 invested in ABVC on Jul 10, 2025 (≈ 298.507471 ABVC) would be worth
$450.75
-$549.25 (-54.9%) today · 0.45× · US Dollar
Based on a ABVC entry price of $3.35 vs. today's $1.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.8 | $838.89 | -16.1% |
| 1 month ago | $1.29 | $1,170.54 | +17.1% |
| 3 months ago | $1.43 | $1,055.94 | +5.6% |
| 6 months ago | $2.08 | $725.96 | -27.4% |
| 1 year ago | $3.35 | $450.75 | -54.9% |
| All time (5.0y) ago | $49.5 | $30.51 | -96.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABVC forecast.
Our base-case forecast reaches $3.00 around 2031.
Implied market cap at $3.00: $78M
The multi-year forecast shows substantial upside potential. In 2026 the average price is projected at $1.45; in 2027 the average is $1.76 with an ROI of 21.6; in 2028 the average is $1.80 with an ROI of 23.9; in 2029 the average is $1.86 with an ROI of 28. By 2030 the average rises to $3.03 with an ROI of 109, followed by 2031 at $3.74 (ROI 158) and 2032 at $4.04 (ROI 178.6), and 2033 at $4.99 (ROI 244.1).
The 2040 forecast shows an average of $7.82 with a max of $17.17 (ROI 439.3), and by 2050 the average is $23.64 with a max of $54.38 (ROI 1530.4). These are estimates and not guarantees, subject to market and operational risks.
Tap a question to reveal the answer.
In 2030, the average price is $3.03, with a min of $1.87 and a max of $5.26, and a forecasted ROI of 109. Sentiment is BULLISH.
The forecast shows bullish sentiment from 2027 onward with upside potential (2031 avg $3.74; ROI 158; 2032 avg $4.04; ROI 178.6; 2050 max $54.38). These are estimates, not guarantees.
Yes. The 2040 max is $17.17 and the 2050 max is $54.38, so a $10 level could be reached within the projection window.
Current price is $1.45 and market capitalization is $37.7M.
The 30-day range runs from $0.9871 to $2.13. The RSI is 50, with SMA50 at $1.31 and SMA200 at $1.91; support is $1.19 and resistance is $2.02.
ABVC BioPharma, Inc. Community Discussion
0Share your ABVC BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.